Commercial payers, large employers and leading provider systems across the nation have fully embraced this transformation and they will not simply revert back to the fee-for-service system of healthcare delivery and reimbursement.
Oluwatobi A. Ogbechie, MD, MBA discusses her 2016 AAD Poster, "Measuring the costs of shave and punch biopsy techniques using time-driven activity-based costing" with Dermatology Times Editorial Advisor, Elaine Siegfried, MD.
Targeted treatments of HER2-positive breast cancers have dramatically prolonged many patients’ lives. But treatment outcomes in clinical trial settings don’t always translate into comparable real-world clinical value.
The combination of unsustainable healthcare spending and the rapid growth of value-based reimbursement revenue models is driving the shift to patient-centered care across the continuum—or continuum-centered care.